Beijing Luzhu Biotechnology Co (HKSE:02480) EPS (Basic): HK$-0.82 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02480 Beijing Luzhu Biotechnology Co Ltd HKSE:02480
24 GF Score
Price HK$13.00
! 3 Warning Signs
View Full Analysis

What is Beijing Luzhu Biotechnology Co EPS (Basic)?

Beijing Luzhu Biotechnology Co HKSE:02480 24 EPS (Basic) is HK$-0.82 as of Dec. 2025. GuruFocus rates HKSE:02480 with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Beijing Luzhu Biotechnology Co's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.40. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.82.

Beijing Luzhu Biotechnology Co's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.40. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.82.

Beijing Luzhu Biotechnology Co's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.39. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.81.

During the past 3 years, the average EPS without NRI Growth Rate was 41.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Beijing Luzhu Biotechnology Co's highest 3-Year average EPS without NRI Growth Rate was 41.60% per year. The lowest was 34.30% per year. And the median was 37.95% per year.

Beijing Luzhu Biotechnology Co  (HKSE:02480) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Beijing Luzhu Biotechnology Co EPS (Basic) Related Terms

Beijing Luzhu Biotechnology Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Beijing Luzhu Biotechnology Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co EPS (Basic) Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-3.26 -4.00 -1.37 -0.89 -0.83

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only -0.92 -0.58 -0.31 -0.43 -0.40
HKSE:02480
24GF Score
Beijing Luzhu Biotechnology Co Ltd HKSE:02480
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Luzhu Biotechnology Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Beijing Luzhu Biotechnology Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-166.101-0)/199.667
=-0.83

Beijing Luzhu Biotechnology Co's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-80.407-0)/198.928
=-0.40

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-0.82 mean?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a EPS (Basic) of HK$-0.82 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Beijing Luzhu Biotechnology Co and its competitors.
Is Beijing Luzhu Biotechnology Co's EPS (Basic) too high?
Beijing Luzhu Biotechnology Co's current EPS (Basic) is HK$-0.82. Overall, Beijing Luzhu Biotechnology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Luzhu Biotechnology Co's EPS (Basic) compare to VRTX and REGN?
Beijing Luzhu Biotechnology Co's EPS (Basic) of HK$-0.82 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Beijing Luzhu Biotechnology Co and its competitors. Beijing Luzhu Biotechnology Co's current EPS (Basic) is HK$-0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Luzhu Biotechnology Co stock overvalued right now?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a current EPS (Basic) of HK$-0.82. The current EPS (Basic) is HK$-0.82. Beijing Luzhu Biotechnology Co's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Beijing Luzhu Biotechnology Co (HKSE:02480), the current EPS (Basic) is HK$-0.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Luzhu Biotechnology Co Business Description

Address No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
24GF Score

Get the complete analysis for HKSE:02480

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$13.00
Price